Impacto do uso de antidepressivos da classe dos ISRS em pacientes oncológicos em tratamento com tamoxifeno para o câncer de mama
Carregando...
Data
2024
Autores
Orientador
Assmann, Juliana
Banca
Gerhardt, Daniéli
Ely, Luisa Scheer
Título do periódico
ISSN
Título do Volume
Editor
Resumo
Objetivo: Identificar a presença de interações medicamentosas entre tamoxifeno e ISRS em pacientes com câncer de mama em um hospital do interior do Rio Grande do Sul. Métodos: Esta pesquisa trata-se de um estudo do tipo exploratório quanti-qualitativo, que se deu a partir da coleta de dados de prontuário. A população foi constituída de pacientes que iniciaram o tratamento com tamoxifeno no período de janeiro de 2022 a dezembro de 2023, do sexo feminino e com diagnóstico de câncer de mama. Foram excluídas as pacientes que vieram a óbito. Resultados: Foram avaliadas 75 pacientes. Quanto ao gene expresso pelo tumor, subdividiu-se em 73,3% em HER 2 Negativo e 26,7% em HER 2 Positivo. O tempo de convívio com a doença foi de 52% para mais de 3 anos e 48% para o tempo de 1 a 2 anos. A classe de antidepressivo utilizada antes do início do tratamento com tamoxifeno foi de 21,3% para a classe ISRS, 14,7% para outras classes de antidepressivos e 64% das pacientes não utilizavam antidepressivos nesse período. Após o início do tratamento com tamoxifeno, 64% das pacientes continuaram sem fazer o uso de antidepressivos, 6,66% das pacientes pararam de fazer uso, 8% trocaram a classe de antidepressivo, enquanto 21,33% continuaram utilizando a mesma classe de antidepressivo. Conclusão: Há uma importante interação entre o tamoxifeno e os antidepressivos da classe dos ISRS e a identificação e intervenção são de extrema importância para o prognóstico clínico. A importância da atuação do profissional farmacêutico se mostra cada vez mais importante e essencial, principalmente dentro do ambiente hospitalar, podendo identificar, intervir e prevenir interações medicamentosas.
Objective: To identify the presence of drug interactions between tamoxifen and SSRIs in patients with breast cancer in a hospital in the interior of Rio Grande do Sul. Methods: This research is an exploratory, quantitative-qualitative study, which will be based on the collection of data from medical records. The population consisted of patients who started treatment with tamoxifen within the period from January 2022 to December 2023, female and diagnosed with breast cancer. Patients who died were excluded. Results: 75 patients were evaluated, 100% of whom were female. The gene expressed by the tumor was subdivided into 73.3% into HER 2 Negative and 26.7% into HER 2 Positive. The length of time living with the disease was 52% for more than 3 years and 48% for 1 to 2 years. The class of antidepressant used before starting treatment with tamoxifen was 21.3% for the SSRI class, 14.7% for other classes of antidepressants and 64% of patients were not using antidepressants during this period. After starting treatment with tamoxifen, 64% of patients continued without using antidepressants, 6.66% of patients stopped using them, 8% changed the class of antidepressant, while 21.33% continued using the same class of antidepressant. Conclusion: There is an important interaction between tamoxifen and SSRI class antidepressants and identification and intervention are extremely important for clinical prognosis. The importance of the pharmaceutical professional's role is increasingly important and essential, especially within the hospital environment, being able to identify, intervene and prevent drug interactions.
Objective: To identify the presence of drug interactions between tamoxifen and SSRIs in patients with breast cancer in a hospital in the interior of Rio Grande do Sul. Methods: This research is an exploratory, quantitative-qualitative study, which will be based on the collection of data from medical records. The population consisted of patients who started treatment with tamoxifen within the period from January 2022 to December 2023, female and diagnosed with breast cancer. Patients who died were excluded. Results: 75 patients were evaluated, 100% of whom were female. The gene expressed by the tumor was subdivided into 73.3% into HER 2 Negative and 26.7% into HER 2 Positive. The length of time living with the disease was 52% for more than 3 years and 48% for 1 to 2 years. The class of antidepressant used before starting treatment with tamoxifen was 21.3% for the SSRI class, 14.7% for other classes of antidepressants and 64% of patients were not using antidepressants during this period. After starting treatment with tamoxifen, 64% of patients continued without using antidepressants, 6.66% of patients stopped using them, 8% changed the class of antidepressant, while 21.33% continued using the same class of antidepressant. Conclusion: There is an important interaction between tamoxifen and SSRI class antidepressants and identification and intervention are extremely important for clinical prognosis. The importance of the pharmaceutical professional's role is increasingly important and essential, especially within the hospital environment, being able to identify, intervene and prevent drug interactions.
Descrição
Palavras-chave
tamoxifen; tamoxifeno; CYP2D6; selective serotonin reuptake inhibitors (SSRIs); drug interaction; breast cancer; cancer de mama; inibidores seletivos da recaptação de serotonina (ISRS); interação medicamentosa
Citação
PETRY, Jéssica Laís. Impacto do uso de antidepressivos da classe dos ISRS em pacientes oncológicos em tratamento com tamoxifeno para o câncer de mama. 2024. Artigo (Graduação) – Curso de Farmácia, Universidade do Vale do Taquari - Univates, Lajeado, 04 dez. 2024. Disponível em: http://hdl.handle.net/10737/4715.